Masatsugu Miyashita

Kyoto, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

MR Imaging/Ultrasound Fusion-Guided Biopsy and Primary Focal Therapy for Localized Prostate Cancer.

MR Imaging/Ultrasound Fusion-Guided Biopsy and Primary Focal Therapy for Localized Prostate Cancer.

Journal: Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine

Published: June 03, 2026

Screening for prognostic indicators in patients with metastatic castration-resistant prostate cancer after androgen receptor signaling inhibitor treatment for metastatic castration-sensitive prostate cancer.

Screening for prognostic indicators in patients with metastatic castration-resistant prostate cancer after androgen receptor signaling inhibitor treatment for metastatic castration-sensitive prostate cancer.

Journal: Japanese journal of clinical oncology

Published: April 04, 2026

Triplet versus doublet therapy in patients with metastatic hormone-sensitive prostate cancer.

Triplet versus doublet therapy in patients with metastatic hormone-sensitive prostate cancer.

Journal: Scientific reports

Published: December 15, 2025

Successful living kidney transplantation in a T-cell flow cytometry crossmatch-positive patient with atypical hemolytic uremic syndrome treated with an anti-C5 antibody: a case report.

Successful living kidney transplantation in a T-cell flow cytometry crossmatch-positive patient with atypical hemolytic uremic syndrome treated with an anti-C5 antibody: a case report.

Journal: CEN case reports

Published: August 01, 2025

Clinical trial evaluating the efficacy and safety of percutaneous prostate cancer lesion-targeted microwave tissue coagulation for prostate functional preservation: MicroPro2.

Clinical trial evaluating the efficacy and safety of percutaneous prostate cancer lesion-targeted microwave tissue coagulation for prostate functional preservation: MicroPro2.

Journal: International journal of surgery protocols

Published: June 04, 2025

Exploratory trial of urethral submucosa injection therapy of deflux for stress urinary incontinence after radical prostatectomy.

Exploratory trial of urethral submucosa injection therapy of deflux for stress urinary incontinence after radical prostatectomy.

Journal: International journal of surgery protocols

Published: June 02, 2025

MRI-Determined Tumor Contact Area as a Predictor of Pathological Extraprostatic Extension in Clinical T2 Prostate Cancer.

MRI-Determined Tumor Contact Area as a Predictor of Pathological Extraprostatic Extension in Clinical T2 Prostate Cancer.

Journal: Prostate cancer

Published: June 01, 2025

Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer.

Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer.

Journal: The Prostate

Published: October 03, 2024

Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer.

Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer.

Journal: Scientific reports

Published: October 09, 2023

Genitourinary malignancies in kidney transplant recipients.

Genitourinary malignancies in kidney transplant recipients.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: July 15, 2023

Treatment impact of newly approved therapeutic agents for metastatic urothelial carcinoma in Japan: a single-center retrospective study.

Treatment impact of newly approved therapeutic agents for metastatic urothelial carcinoma in Japan: a single-center retrospective study.

Journal: Scientific reports

Published: May 26, 2023

Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients.

Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients.

Journal: World journal of urology

Published: August 17, 2022

Showing 1-12 of 18

Last Updated: 09/26/2026